Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Hypertension,Essential
Phase Not Applicable
Enrollment 20000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The main purpose of this observation study is to collect data on the effects and side effects for 12 weeks of the medication administration of the single-pill combinations, which are fimasartan/amlodipine or fimasartan/amlodipine/hydrochlorothiazide, based on fimasartan. (Stage 1). Also, this study will evaluate major cardiovascular events, long-term blood pressure control, and the safety by follow-up of those who consent to the extended study for about 2 years (96 weeks).(Stage 2)

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • The blood pressure control rate (Week 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-06-23
Completion: 2026-06
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Boryung Pharmaceutical Co., Ltd
Principal Investigators:
  • MyungSook Hong (STUDY_DIRECTOR) - Boryung Co.,Ltd.
Contact Information
Study Contact:
MyungSook Hong
+8227088238
mshong@boryung.co.kr
JiYeon Kim
+8227088128
jiyeonkim@boryung.co.kr
InHo Chae, M.D., Ph.D.
Seoul National University Bundang Hospital
Interventions
N/A
Study Locations (1 sites)
Seoul National University Bundang Hospital, Seoul, South Korea
Eligibility Criteria
* Inclusion Criteria: 1. Patients who voluntarily consent on the informed consent form and understand the study's purpose, methods, and so on 2. Males and females over the age of 19 3. Patients who have been diagnosed with essential hypertension and plan to be treated with fimasartan/amlodipine or fimasartan/amlodipine/hydrochlorothiazide If the patient is applicable, one of the following; * If the patients have severe hypertension, stage 2 or higher(sit SBP ≥ 160 mmHg or sit DBP ≥ 100 mmHg), or high-risk hypertension (The cardiovascular risk score of the 2018 hypertension treatment guidelines by the Korean Society of Hypertension is applied.) The patients have never been treated with antihypertensive drugs for essential hypertension. * If the patients are on concomitant administration of fimasartan/amlodipin and hydrochlorothiazide for essential hypertension or, If the patients are on concomitant administration of a fimasartan/hydrochlorothiazide combination and amlodipine for essential hypertension * If the patients have a blood pressure of sitSBP ≥ 140 mmHg or sitDBP ≥ 90 mmHg even though they have been treated with antihypertensive drugs for essential hypertension 4. The patients who understand this study and are available to participate in this study until the end of the study period with a cooperative attitude. * Exclusion Criteria: 1. The patients who are suspected of having secondary hypertension or confirmed to have secondary hypertension 2. The patients who are contraindicated to taking fimasartan complex according to the drug labelling 3. The patients who are currently participation in another clinical trials (Drugs or medical devices) The patients who took an investigational drug within 12 weeks of the enrollment date However, the following patients can participate in this study: The patients who are currently enrolled in non-interventional clinical studies or who are being followed up on after the administration of investigational drugs has ended. 4. The patients who are not suitable for this study by the investigators
Conditions Hypertension
Phase Not Applicable
Enrollment 3000
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The aim of the research is to evaluate the Subendocardial Viability Ratio (SEVR) in hypertensive patients, using non-invasive arterial tonometry, and to establish the influencing factors and the possibility of predicting cardiovascular morbidity and mortality in arterial hypertension. The SEVR will be evaluated on all patients belonging to the Arterial Hypertension Centers undergoing non-invasive arterial tonometry. The SEVR is calculated on the morphology of the central pressure wave as the ratio between the DPTI (diastolic pressure-time index), i.e. the area between the carotid pressure curve and the ventricular pressure curve during the diastolic phase, and the SPTI ( systolic pressure-time index), i.e. the area under the carotid pressure curve during the systolic phase. The SEVR will be correlated with the anthropometric and pathology variables which will be collected in an appropriate database.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Arterial tonometry — Arterial transcutaneous tonometry

Primary Outcomes

  • Buckberg index (At recruitment, at 1 year, 2 years, 3 years and 4 years of follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-10-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 3000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istituto Auxologico Italiano
Contact Information
Study Contact:
Paolo Salvi, MD
+390261911
p.salvi@auxologico.it
Antonino Di Guardo, MD
ninodiguardo58@gmail.com
Centro di Prevenzione e Cura dell'Ipertensione Arteriosa "Alessandro Filippi"
Massimo Catanuso, MD
catanusomassimo@hotmail.it
Centro di Prevenzione e Cura dell'Ipertensione Arteriosa "Alessandro Filippi"
Interventions
  • Diagnostic Test: Arterial tonometry — Arterial transcutaneous tonometry
Study Locations (5 sites)
Centro di Prevenzione e Cura dell'Ipertensione Arteriosa "Alessandro Filippi", Mascalucia, Catania Italy
Unità Operativa Semplice Dipartimentale Ipertensione Arteriosa "Anna Maria Pirrelli", Università degli Studi di Bari "Aldo Moro". Policlinico Consorziale di Bari, Bari, Italy
Istituto Auxologico Italiano IRCCS, Milan, 20145 Italy
Medicina II Cardiovascolare, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Dipartimento di Scienze Mediche, Chirurgiche e della Salute, Università degli studi di Trieste, Trieste, Italy
Eligibility Criteria
Inclusion Criteria: * Hypertension Exclusion Criteria: * Atrial fibrillation
Conditions Invasive Mammary Carcinoma, Metastatic B...
Phase PHASE2
Enrollment 64
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Capecitabine — 2000 mg taken by mouth twice daily for 7 days on, 7 days off
  • Other: Endocrine-therapy — Endocrine therapy administered
  • Other: MammoPrint ® and BluePrint assays — Archival tissue will be analyzed using the MammoPrint ® and BluePrint assays

Primary Outcomes

  • Progression free survival (Up to 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-09-28
Completion: 2037-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 64 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sonya Reid
Collaborators: Agendia, Susan G. Komen Breast Cancer Foundation
Principal Investigators:
  • Sonya Reid, MD (PRINCIPAL_INVESTIGATOR) - Vanderbilt University/Ingram Cancer Center
Contact Information
Study Contact:
Vanderbilt-Ingram Services for Timely Access
800-811-8480
cip@vumc.org
Kyndall Thomas
University of Alabama Birmingham
Nusrat Jahan
University of Alabama Birmingham
Interventions
  • Drug: Capecitabine — 2000 mg taken by mouth twice daily for 7 days on, 7 days off
  • Other: Endocrine-therapy — Endocrine therapy administered
  • Other: MammoPrint ® and BluePrint assays — Archival tissue will be analyzed using the MammoPrint ® and BluePrint assays
Study Locations (3 sites)
University of Alabama Birmingham, Birmingham, Alabama 35249 United States
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee 37232 United States
UT Southwestern Medical Center, Dallas, Texas 75390 United States
Eligibility Criteria
Inclusion Criteria: * Signed and dated written informed consent. * Subjects ≥ 18 years of age. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. * Clinical stage IV invasive mammary carcinoma or unresectable locoregional recurrence of invasive mammary carcinoma that is: * ER (\>/=1%) and/or PR (\>/= 1%) by IHC and HER2 negative (by IHC or FISH) * Previously exposed to an aromatase inhibitor (AI) or a selective estrogenreceptor modulator/ downregulator (SERM; SERD) + a CDK4/6 inhibitor. * Prior radiation permitted (if completed at least 2 weeks prior to study entry. Patients who have received prior radiotherapy must have recovered from toxicity (≤ grade 1) induced by this treatment (except for alopecia) * Patients with brain metastasis secondary to breast cancer and clinically stable for more than 4 weeks from completion of radiation treatment and off steroids * Evaluable disease (measurable or non-measurable) * Measurable disease, ie, at least 1 measurable lesion as per RECIST 1.1 (a lesion at a previously irradiated site may only be counted as a target lesion if there is clear sign of progression since the irradiation) * Patients with bone only disease allowed if possible to evaluate on radiological exams (eg.bone scan, PET/CT, CT, MRI) even if lesions are non-measurable according to RECIST1.1. * Adequate organ function including: * Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L * Platelets ≥ 100 × 10\^9/L * Hemoglobin ≥ 8/g/dL (may have been transfused) * Total serum bilirubin ≤ 1.5 times upper limit of normal (ULN) * Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 2.5 × ULN (or ≤ 5 × ULN if liver metastases are present) * Serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥ 50mL/min as calculated using the Cockcroft-Gault (CG) equation * For randomized patients only: tumors must be diagnosed as non-Luminal A using the Blueprint® and Mammaprint® tests Exclusion Criteria: * Prior chemotherapy in the metastatic setting * Previous malignant disease other than breast cancer within the last 2 years with associated competing risk, with the exception of basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, or low-risk cancers considered curatively treated (i.e. complete remission achieved at least 2 years prior to first dose of study drugs AND additional therapy not required while receiving study treatment). * Persisting symptoms related to prior therapy that has not reduced to Grade 1 \[National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 5.0\]; however, menopausal symptoms, alopecia, and sensory neuropathy Grade ≤ 2 is acceptable * Pregnant or breastfeeding females.
Conditions Advanced Solid Tumors, Breast Cancer, No...
Phase PHASE1, PHASE2
Enrollment 414
Locations 20 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter, open-label, phase Ib/II study of YL202 in combination with other anti-tumor therapies to Evaluate the Safety, Tolerability, and Efficacy in Patients with Advanced Solid Tumors

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: YL202 for injection; Toripalimab injection — Part 1: YL202 and Toripalimab will be administered intravenously. Part 3: participants will receive escalating doses of YL202 and fixed dose of Toripalimab until YL202 doses for optimization are determined. Dose expansion stage: participants will receive a dose of YL202 not exceeding the maximum dose level achieved during the dose-escalation stage and fixed dose of Toripalimab
  • Drug: YL202 for injection; Furmonertinib Mesilate Tablets — Part 2: YL202 will be administered intravenously,Furmonertinib Mesilate Tablets will be administered orally. Dose escalation stage: participants will receive escalating doses of YL202 and fixed dose of Furmonertinib Mesilate until YL202 doses for optimization are determined. Part 4: participants will receive a dose of YL202 not exceeding the maximum dose level achieved during the dose-escalation stage and fixed dose of Furmonertinib Mesilate.

Primary Outcomes

  • Nature and frequency of dose-limiting toxicity (DLT) (21 days after the first dose was administered to each subject.)
  • Nature and frequency of adverse events (AEs) (42 days after the end of treatment (EOT).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-09-02
Completion: 2027-11-30
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 414 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
Contact Information
Study Contact:
Ning Wang, MM
+86 0512-62858368
info@medilinkthera.com
Study Coordinator
Anhui Provincial Hospital(The First Affiliated Hospital of Ustc)
Study Coordinator
Fujian Cancer Hospital
Interventions
  • Drug: YL202 for injection; Toripalimab injection — Part 1: YL202 and Toripalimab will be administered intravenously. Part 3: participants will receive escalating doses of YL202 and fixed dose of Toripalimab until YL202 doses for optimization are determined. Dose expansion stage: participants will receive a dose of YL202 not exceeding the maximum dose level achieved during the dose-escalation stage and fixed dose of Toripalimab
  • Drug: YL202 for injection; Furmonertinib Mesilate Tablets — Part 2: YL202 will be administered intravenously,Furmonertinib Mesilate Tablets will be administered orally. Dose escalation stage: participants will receive escalating doses of YL202 and fixed dose of Furmonertinib Mesilate until YL202 doses for optimization are determined. Part 4: participants will receive a dose of YL202 not exceeding the maximum dose level achieved during the dose-escalation stage and fixed dose of Furmonertinib Mesilate.
Study Locations (20 sites)
Anhui Provincial Hospital(The First Affiliated Hospital of Ustc), Hefei, Anhui 230001 China
Fujian Cancer Hospital, Fuzhou, Fujian 350014 China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510555 China
Meizhou People's Hospital(Huangtang Hospital)Meizhou Academy of Medical Sciences, Meizhou, Guangdong 514031 China
Ghang xi Medical University Cancer Hospital, Nanning, Guangxi 530028 China
Affiliated Hospital Of Hebei University, Baoding, Hebei 71051 China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081 China
Anyang Cancer Hospital, Anyang, Henan 455100 China
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471023 China
Xiangyang Central Hospital, Xiangyang, Hubei 441138 China
Eligibility Criteria
Inclusion Criteria: 1. Informed of the study before the start of the study and voluntarily sign their name and date in the informed consent form (ICF) 2. Able and willing to comply with protocol visits and procedures 3. Aged between 18 to 75 years 4. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 5. Previously treated by standard treatment or have not been treated for metastatic setting; 6. Adequate organ and bone marrow function. 7. Have at least 1 extracranial measurable tumor lesion. 8. Adequate archival formalin-fixed paraffin embedded (FFPE) tissue from prior biopsy. Exclusion Criteria: 1. With prior drug therapy targeting HER3 (including antibodies, antibody-drug conjugates \[ADCs\]), chimeric antigen receptor T-cell immunotherapy (CAR-T), and other drugs). 2. Previously intolerant to topoisomerase I inhibitors or ADC therapy composed of topoisomerase I inhibitors. 3. Are participating in another clinical study, unless it is an observational (non-interventional) clinical study or in the follow-up period of an interventional study. 4. The washout period from the previous anti-tumor therapy is insufficient before the first dose of the investigational product. 5. Patients who have received major surgery (excluding diagnostic surgery) within 4 weeks before the first dose of the investigational product or those who are expected to receive major surgery during the study. 6. Prior treatment with allogeneic bone marrow transplantation or solid organ transplantation. 7. Prior treatment with systemic steroids (prednisone \> 10 mg/day or equivalent) or other immunosuppressive treatment within 2 weeks before the first dose of the investigational product. 8. Patients who have received any live vaccine within 4 weeks before the first dose of the investigational product or those who plan to receive live vaccine during the study period. 9. With meningeal metastasis or cancerous meningitis. 10. With brain metastasis or spinal cord compression. 11. Patients with uncontrolled or clinically significant cardiovascular diseases. 12. Clinically significant complicated pulmonary disorders. 13. Patients diagnosed with Gilbert syndrome. 14. Those with uncontrolled effusion in the third space requiring repeated drainage. 15. With a medical history of gastrointestinal perforation and/or fistula within 6 months before the first dose, or with active gastric and duodenal ulcers, ulcerative colitis, or other gastrointestinal diseases that may lead to hemorrhage or perforation according to the investigator. 16. With serious infection before the first dose. 17. With known human immunodeficiency virus (HIV) infection. 18. With active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. 19. With a medical history of any other primary malignancies within 5 years before the first dose of the investigational product. 20. Unrelieved toxicity of previous anti-tumor therapy. 21. With a history of severe hypersensitivity to inactive ingredients in the raw materials and drug product or other monoclonal antibodies. 22. Lactating women, or women who are confirmed pregnant via a pregnancy test within 3 days before the first dose. 23. With any diseases, medical conditions, organ system dysfunction, or social conditions that may interfere with the ability of subjects to sign the ICF, adversely affect the ability of subjects to cooperate and participate in the study, or affect the interpretation of study results, including but not limited to mental illness or substance/alcohol abuse, in the opinion of the investigator.
Conditions Breast Cancer Survivors
Phase Not Applicable
Enrollment 420
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to look at how differences in cognitive (mental) function develop over time in breast cancer survivors compared to volunteers without a history of cancer (healthy volunteers). Both cancer survivors and healthy volunteers (who are the same age as the cancer survivors) will participate in this study so the researchers can compare the results of neurocognitive testing (which looks at memory, attention, and information processing) on each group of participants.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Other: Assessments — Sociodemographics, Deficit Accumulation Questionnaires, Remote Cognitive Assessment, Deficit Accumulation Questionnaires,Remote Cognitive Assessment
  • Other: Assessment (Survivors Only) — \*Tumor/Treatment Variables (Survivors Only)
  • Other: APOE and DNA Isolation — Biospecimens procurement and processing

Primary Outcomes

  • examine cognitive effects (within 45 days of participant consent)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-05-10
Completion: 2028-08-31
Eligibility
Age: 60 Years – 80 Years
Sex: FEMALE
Volunteers: true
Enrollment: 420 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigators:
  • James Root, PhD (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
James Root, PhD
646-888-0035
rootj@mskcc.org
Denise Correa, PhD
212-610-0491
James Root, PhD
646-888-0035
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Interventions
  • Other: Assessments — Sociodemographics, Deficit Accumulation Questionnaires, Remote Cognitive Assessment, Deficit Accumulation Questionnaires,Remote Cognitive Assessment
  • Other: Assessment (Survivors Only) — \*Tumor/Treatment Variables (Survivors Only)
  • Other: APOE and DNA Isolation — Biospecimens procurement and processing
Study Locations (7 sites)
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey 07920 United States
Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey 07748 United States
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey 07645 United States
Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack, New York 11725 United States
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York 10604 United States
Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States
Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York 11553 United States
Eligibility Criteria
Inclusion Criteria: All Participants: * Per medical record and/or self-report, identifies as female * Per medical record and/or self-report, currently age 60-80 * Per self-report, has access to a computer and internet connectivity * Score of \<11 on Blessed Orientation-Memory-Concentration Test (BOMC) * As per medical record or self-report, if currently taking psychoactive medications (including but not limited to antidepressants and anxiolytics), dose must have been stable at least two months prior to enrollment. * English fluent (as per self-report, fluency of "well" or "very well", and having a reasonable comprehension of the study conversation in the opinion of the research staff)\*\* Breast Cancer Survivors: * Per medical record and/or self-report, history of stage 0-3 breast cancer diagnosed between 50-60 years of age * Per medical record and/or self-report, no evidence of disease (NED) Non-Cancer Controls: * Per self-report, no history of breast cancer * Language verification: For both survivors and controls, prior to enrollment, all will be asked the following two questions by a CRC to verify English fluency necessary for participation in the study: 1. How well do you speak English? (must respond "Well" or "Very well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused) 2. What is your preferred language for healthcare? (must respond English) Exclusion Criteria: All participants: * As per medical record or self-report, diagnosis of neurodegenerative disorder that affects cognitive function (e.g. Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, Dementia, Seizure Disorders, etc.) * As per medical record or self-report, history of stroke or head injury resulting in a structural lesion on neuropsych imaging, persistent cognitive difficulties impacting work or daily life, or required cognitive rehabilitation * As per medical record or self-report, a diagnosis of a major Axis I psychiatric disorder including Schizophrenia Spectrum Disorder, substance use disorder, Bipolar Disorder or Schizotypal personality disorder. Schizophrenia Spectrum Disorders include Schizophrenia, Schizophreniform disorder, Schizoaffective disorder, Delusional disorder, Brief psychotic disorder, and Attenuated Psychotic Disorder. * As per medical record or self-report, visual or auditory impairment that would preclude ability to complete the assessments (e.g. history of significant macular degeneration or being unable to correct hearing with hearing aids) * As per medical record or self-report, use of methotrexate (Amethopterin, Rhematrex, Trexall) or rituximab (Rituxin) for rheumatoid arthritis, psoriasis or Crohn's disease, or cyclophosphamide (Cytoxan, Neosar) for lupus. * As per medical record or self-report, participation in a conflicting (overlapping neurocognitive assessments) research study (i.e. MSK 18-294) Breast Cancer Survivors: * As per medical record or self-report, history of cancer recurrence * As per medical record or self-report, any history of another cancer except nonmelanoma skin cancer or first breast cancer (a secondary breast cancer is exclusionary) * As per medical record or self-report, breast cancer only treated with surgery Non-Cancer Controls: * As per medical record or self-report, history of treatment using radiation, chemotherapy, and/or Tamoxifen or Aromatase-inhibitors * As per medical record or self-report, any history of cancer except non-melanoma skin cancer
Conditions Solid Tumor, Non-small Cell Lung Cancer,...
Phase PHASE1
Enrollment 299
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors. The study will also identify the recommended dose for future studies. The trial includes two phases and is expected to last about 4 years, with treatment and follow-up lasting approximately 6-12 months each.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: HH160 — Administered by intravenous infusion on Day 1 of each 21-day (Q3W) cycle or 14-day (Q2W) cycle.

Primary Outcomes

  • Phase 1a: Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (From first dose of study drug to 30 days after last dose or initiation of a new anticancer therapy, whichever occurs first; up to approximately 12 months)
  • Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of HH160 (From first dose through the end of Cycle 1 (approximately 1 month))
  • Phase 1b: Recommended Phase 2 Dose (RP2D) of HH160 (From first dose through completion of Phase 1b dose optimization (up to 2 years))
  • Phase 1b: Overall Response Rate (ORR) (Up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-06-11
Completion: 2028-08
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 299 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Huahui Health
Collaborators: BeOne Medicines
Principal Investigators:
  • Study Director (STUDY_DIRECTOR) - BeOne Medicines
Contact Information
Study Contact:
Medical Officer
+86-010-80766688
zhouxin@hhhbio.com
Study Director
1-877-828-5568
clinicaltrials@beonemed.com
Interventions
  • Drug: HH160 — Administered by intravenous infusion on Day 1 of each 21-day (Q3W) cycle or 14-day (Q2W) cycle.
Study Locations (3 sites)
Calvary Mater Newcastle, Waratah, New South Wales 2298 Australia
Tasman Health Care, Southport, Queensland 4215 Australia
Shandong Tumour Hospital Dongyuan Unit, Jinan, Shandong China
Eligibility Criteria
Key Inclusion Criteria 1. Adults aged 18 to 75 years with signed informed consent. 2. Histologically or cytologically confirmed advanced solid tumors meeting phase-specific disease requirements. 3. At least 1 measurable lesion per RECIST v1.1. 4. Eastern Cooperative Oncology Group Performance Status (ECOG) Performance Status of 0 or 1 with life expectancy ≥ 12 weeks. 5. Adequate organ function based on protocol-specified laboratory criteria. Key Exclusion Criteria 1. Active leptomeningeal disease or uncontrolled/untreated brain metastases. 2. History of severe hypersensitivity reactions to monoclonal antibodies, bispecific antibodies, trispecific antibodies, or study drug components. 3. Other malignancy within 3 years prior to first dose, except specified curatively treated cancers. 4. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage. 5. Significant bleeding risk, severe coagulopathy, gastrointestinal hemorrhage, or recent pulmonary hemorrhage/hemoptysis. NOTE: Other eligibility criteria may apply.
Conditions Breast Cancer
Phase NA
Enrollment 126
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

PhActHealth is a multicenter randomized controlled trial enrolling women with newly diagnosed luminal B or triple-negative breast cancer (BC) who are candidates for neoadjuvant therapy. The study aims to investigate the effects of a preoperative, unsupervised exercise training program on exercise capacity, as well as on immune response, autonomic nervous system (ANS) regulation, cardiovascular health, and tumor aggressiveness prior to surgical removal. Participants are randomly assigned to either an intervention group or a control group. All patients receive lifestyle counseling, while those in the intervention group additionally follow a personalized aerobic and resistance exercise program throughout the neoadjuvant treatment period before surgery. The primary outcome is the improvement in exercise capacity. The secondary outcomes are tumor-specific and systemic responses to the intervention, evaluated by analyzing molecular, metabolic, and inflammatory markers, as well as clinical and functional parameters.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Pre-habilitation exercise program — Participants undertake a 16-week personalized pre-habilitation exercise training program as follows: * Aerobic training: five times per week with an initial session duration set at 45 minutes.The initial target intensity is set at 40% of the Heart Rate Reserve (HRR). Both duration and intensity are progressively increased based on individual exercise tolerance, aiming for an intensity of approximately 60% HRR and a duration of 60 minutes per session. * Resistance training: twice per week, ensuring at least 24-48 hours of recovery between sessions. Patients follow the prescribed number of sets and repetitions demonstrated in in the video tutorials provided by the study staff.

Primary Outcomes

  • Exercise capacity (Baseline and 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-01
Completion: 2029-02-28
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 126 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Milan
Collaborators: University of Urbino "Carlo Bo", Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Istituto Auxologico Italiano
Principal Investigators:
  • Francesca Bianchi, PhD (PRINCIPAL_INVESTIGATOR) - University of Milan
  • Christine Desmedt, PhD (PRINCIPAL_INVESTIGATOR) - Laboratory for Translational Breast Cancer Research, Ku Leuven
  • Valentina Bollati, PhD (PRINCIPAL_INVESTIGATOR) - University of Milan
Contact Information
Study Contact:
Elia M Biganzoli, Professor
+39 02503 19652
elia.biganzoli@unimi.it
Roberta Biciuffi, MSc
roberta.biciuffi@unimi.it
Ornella Garrone
ornella.garrone@policlinico.mi.it
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Interventions
  • Behavioral: Pre-habilitation exercise program — Participants undertake a 16-week personalized pre-habilitation exercise training program as follows: * Aerobic training: five times per week with an initial session duration set at 45 minutes.The initial target intensity is set at 40% of the Heart Rate Reserve (HRR). Both duration and intensity are progressively increased based on individual exercise tolerance, aiming for an intensity of approximately 60% HRR and a duration of 60 minutes per session. * Resistance training: twice per week, ensuring at least 24-48 hours of recovery between sessions. Patients follow the prescribed number of sets and repetitions demonstrated in in the video tutorials provided by the study staff.
Study Locations (2 sites)
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
University of Urbino "Carlo Bo", Urbino, Italy
Eligibility Criteria
Inclusion Criteria: * being a patient with first diagnosis of primary BC; * luminal BC tumor subtype B defined as positive for estrogen and/or progesterone receptor expression, HER2 negative and high Ki-67; or triple Negative BC tumor subtype defined as negative for estrogen and/or progesterone receptor expression, HER2 negative, defined by the Pathology and Medical Oncology units as defined by the ESMO Guidelines Committee (referred to the American Society of Clinical Oncology/College of American Pathologists guidelines for assessment of hormone receptor (HR) status (i.e. ER and 4 PgR)25 and HER2 status, and by the International Ki-67 in Breast Cancer Working Group for Ki-67); * candidate for chemotherapy/immunotherapy neoadjuvant treatment; * signed informed consent for study participation; * declared being not engaged in any competitive or recreational physical activity. Exclusion Criteria: * therapeutic modifications during the intervention period; * presence of chronic conditions (such as autoimmune diseases, neurodegenerative diseases, psychiatric disorders/cognitive disabilities, chronic obstructive pulmonary disease); * presence of any condition that significantly impairs the ability to perform exercise; * pregnancy/lactation/intention to initiate pregnancy; * prior chemotherapy or immunotherapy within the past three years; * high baseline physical activity level (i.e. performing exercise at a dose of 600 MET minutes a week or greater, according to the score of the International Physical Activity Questionnaire \[IPAQ\]).
Conditions Breast Cancer, Aromatase Inhibitor Assoc...
Phase EARLY_PHASE1
Enrollment 30
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

Both Tart Cherry and Omega 3 FAs have better side effect profiles compared to other commonly used medications for AIMSS, such as nonsteroidal anti-inflammatories, steroids, and serotonin norepinephrine reuptake inhibitors. Additionally, in our clinics we often find that patients tend to be more receptive to taking a supplement as opposed to an additional medication. Further, both Tart Cherry concentrate and fish oil have beneficial properties for helping with joint stiffness in general, in addition to other health issues like insomnia. There is preliminary evidence in mouse models that when given together, these supplements may have an even greater anti-inflammatory effect than when taken separately14. Although to our knowledge, no human studies have tested this hypothesis. This study has been designed to test the hypothesis that Tart Cherry and fish oil when given in combination over a 12-week period could produce beneficial changes in joint function when compared to Tart Cherry or fish oil in isolation in an obese breast cancer population experiencing AIMSS. Secondary outcomes to be assessed include pain, functional performance, quality of life and cognition.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Drug: Tart Cherry — 1 ounce of Tart Cherry Concentrate (King Orchard) mixed with 8 ounces of water daily for 12 weeks
  • Drug: Omega 3 FA (Fish Oil) — 2 capsules of Omega 3 FA (Fish Oil) (Nordic Naturals Ultimate Omega) \[650 mg EPA and 450 mg DHA per capsule\] daily for 12 weeks

Primary Outcomes

  • The primary objective is to assess changes in joint function between groups. (6 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2025-09-12
Completion: 2027-10
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Philip Chang
Collaborators: Cherry Marketing Institute
Principal Investigators:
  • Philip Chang, DO (PRINCIPAL_INVESTIGATOR) - Cedars-Sinai Medical Center
Contact Information
Study Contact:
Clinical Trial Navigator
310-423-5842
GroupCancerTrialInformation@cshs.org
Clinical Trial Recruitment Navigator
310-423-5842
GroupCancerTrialInformation@cshs.org
Cedars-Sinai Medical Center
Philip Chang, MD
Cedars-Sinai Medical Center
Interventions
  • Drug: Tart Cherry — 1 ounce of Tart Cherry Concentrate (King Orchard) mixed with 8 ounces of water daily for 12 weeks
  • Drug: Omega 3 FA (Fish Oil) — 2 capsules of Omega 3 FA (Fish Oil) (Nordic Naturals Ultimate Omega) \[650 mg EPA and 450 mg DHA per capsule\] daily for 12 weeks
Study Locations (2 sites)
Cedars-Sinai Medical Center, Los Angeles, California 90048 United States
CS Cancer at the Hunt Cancer Center, Torrance, California 90505 United States
Eligibility Criteria
Inclusion Criteria: * Breast cancer diagnosis (Stage I-III) with any hormonal status. * Females aged ≥ 18 years. * Currently receiving AI therapy. * BMI ≥ 27. * Clinical diagnosis of AIMSS. * Omega-3 Index \&lt;8%. * Average joint pain score ≥ 4 on the Brief Pain Inventory (BPI) within 7 days of enrollment. * Written informed consent obtained from subject and ability and willingness of subject to comply with the requirements of the study. Exclusion Criteria: * Current use of anticoagulant medications (Including but not limited to Warfarin, Lovenox, Eliquis, Xarelto). * Allergy to cherries or fish/fish products. * Lifetime history of rheumatoid arthritis and/or inflammatory joint diseases (Including but not limited to reactive arthritis, ankylosing spondylitis, and psoriatic arthritis). * Uncontrolled diabetes mellitus as determined by treating physician (with or without the use of glucose lowering medications and/or insulin). * Lifetime history of stroke or transient ischemic attacks. * New use or dose change of oral or topical analgesics in the previous 14 days. (Including but not limited to opioids, non-steroidal anti-inflammatories, acetaminophen, SNRI's, SSRI's, gabapentinoids, tricyclic antidepressants, and muscle relaxants). * Oral or intra-articular steroid use in the previous 30 days (Including but not limited to dexamethasone, prednisone, methylprednisolone, triamcinolone, hydrocortisone). * History of joint fracture or surgery of the symptomatic joint in the previous 6 months.
Conditions Breast Cancer, Radiotherapy; Complicatio...
Phase PHASE3
Enrollment 1650
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

Locally advanced breast cancer has high-risk local regional recurrence after surgery. Radiotherapy could reduce the local regional recurrence and improve disease free survival and overall survival. Regional lymph node irradiation is the important part of breast cancer radiotherapy. However, there are some controversies about regional lymph node delineation, especially the supraclavicular irradiation volume. Many studies had confirmed that posterolateral region of the supraclavicular fossa (also named Posterior neck lymph node) had a high risk involvement based on the mapping of recurrence nodes. This randomized phase III trial compares medial supraclavicular lymph node irradiation with entire supraclavicular lymph node irradiation in patients with pathologically positive axillary lymph node and high risk of recurrence after mastectomy or breast conservative surgery. It is not yet known if radiation works better with entire supraclavicular fossa than medial supraclavicular fossa.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Entire supraclavicular lymph node radiotherapy — Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node. Entire supraclavicular lymph node includes medial supraclavicular and posterior neck lymph node.
  • Radiation: Medial supraclavicular lymph node radiotherapy — Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node.

Primary Outcomes

  • Disease free survival (DFS ) (Up to 5 years after completion of radiation therapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2021-09-20
Completion: 2027-08
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 1650 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Collaborators: The First Affiliated Hospital of University of Science and Technology of China, Quanzhou First Hospital, Jiangyin People's Hospital, Affiliated Hospital of Jiangnan University, Guizhou Provincial People's Hospital
Principal Investigators:
  • Zhaozhi Yang, M.D (PRINCIPAL_INVESTIGATOR) - Fudan University
  • Xiaomao Guo (STUDY_CHAIR) - Fudan University
Contact Information
Study Contact:
Zhaozhi Yang, M.D.
86 18017317126
yzzhi2014@163.com
Zhaozhi C Yang
+8618017317126
yzzhi2014@163.com
Fudan University Shanghai Cancer Center
Interventions
  • Radiation: Entire supraclavicular lymph node radiotherapy — Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node. Entire supraclavicular lymph node includes medial supraclavicular and posterior neck lymph node.
  • Radiation: Medial supraclavicular lymph node radiotherapy — Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node.
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality China
Eligibility Criteria
Inclusion Criteria: 1. ECOG 0-1 2. Newly diagnosed invasive breast cancer 3. Initial clincial diagonosis stage is T1-4, N0-3a/b, M0: If neoadjuvant chemotherapy was not administered: pathological stage is T1-3N2-3a/b, M0; If neoadjuvant chemotherapy was administered:clinical stage III or pathological stage is T1-4N1-3a/bM0. 4. Underwent breast conservative surgery or Mastectomy with or without breast reconstruction with clear negative margin. At least, axillary level I and level II should be cleared with ≥10 lymph node (including the number of sentinal lymph node) . Level III dissection and internal mamamry node dissection are not required, but may be performed at the discretion of the surgeon. 5. Should receive ≥6 cycles standard neoadjuvant and/or adjuvant chemotherapy (taxane and/or anthracycline based). 6. Enrolled on the trial within 12 weeks of the later of two dates: the final breast cancer surgical procedure or administration of the last cycle of cytotoxic chemotherapy. 7. For ER and/or PR positive patients, the duration of anticipated endocrine therapy should be≥5 year ; For HER2 postive patients, the duration of anticipated herceptin should be 1 year. 8. Writtern, informed consent. Exclusion Criteria: 1. Initinal clinical diagnosis N3c (supraclavicualr node metastasis) 2. T4 or inflamed breast cancer with no good downstage by neoadjuvant chemotherapy 3. Distant metastasis 4. Bilateral breast cancer or previously contralateral breast cancer 5. Positve sentinal lymph node with no axillary dissection 6. ECOG ≥2 7. Could not tolerate chemotherapy and anti-HER2 target treatment 8. Active infectious 9. History of radiotherapy 10. Serious medical complcation 11. Breast cancer during pregnancy and lactation 12. Had simultaneousl or previous secondary malignancies, except for skin basal cell carcinoma and cervical carcinoma in situ. 13. Inaccessibility for follow-up \-
Conditions HR-positive/HER2-negative Breast Cancer
Phase PHASE2
Enrollment 55
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Iparomlimab and Tuvonralimab — 5.0mg/kg qw, start from C1D15
  • Drug: Paclitaxel — 80mg/m\^2 qw
  • Drug: Carboplatin — AUC=1.5, D1, 8, 15, every 28 days

Primary Outcomes

  • Proportion of patients with pCR (1-2 weeks after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-05-01
Completion: 2031-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 55 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: RenJi Hospital
Principal Investigators:
  • Wenjin Yin (PRINCIPAL_INVESTIGATOR) - Renji Hospital, School of Medicine, Shanghai Jiaotong University
Contact Information
Study Contact:
Wenjin Yin
86(21)68385569
yinwenjin@renji.com
Wenjin Yin
86(21)68385569
yinwenjin@renji.com
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Interventions
  • Drug: Iparomlimab and Tuvonralimab — 5.0mg/kg qw, start from C1D15
  • Drug: Paclitaxel — 80mg/m\^2 qw
  • Drug: Carboplatin — AUC=1.5, D1, 8, 15, every 28 days
Study Locations (1 sites)
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127 China
Eligibility Criteria
Inclusion Criteria: * Aged ≥18 years * Histologically confirmed hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative breast cancer * Subjects with at least one evaluable lesion * ECOG 0-1 * Adequate organ function Exclusion Criteria: * Metastatic disease (Stage IV) * Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test;Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period
Conditions Breast Neoplasms
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The main purpose of this study is to compare genetic markers present on tumor cells before and after chemotherapy.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Peripheral blood draw
  • Procedure: Breast tissue collection
  • Procedure: Bone marrow biopsy

Primary Outcomes

  • Characterize tumor markers expressed by DTC which are present after systemic therapy (Approximately 6 years)
  • Compare the expression of these markers to that on DTC detected prior to systemic therapy (Approximately 6 years)
  • Correlate expression of the defined tumor markers on DTC with clinical outcome of breast cancer patients to identify those markers that are predictive of disease recurrence. (Approximately 6 years)
  • Compare the tumor markers present on DTC before and after chemotherapy with the tumor marker expression of the primary tumor and post-treatment tumor. (Approximately 6 years.)
  • To xenograft tumor cells into mice for further genetic and phenotypic characterization. (Approximately 6 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2005-09-14
Completion: 2026-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Washington University School of Medicine
Principal Investigators:
  • Rebecca Aft, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR) - Washington University School of Medicine
Contact Information
Study Contact:
Rebecca Aft, MD, PhD
314-747-0063
aftr@wustl.edu
Rebecca Aft, MD, PhD
314-747-0063
aftr@wustl.edu
Washington University School of Medicine
Tracey Guthrie
314-747-4404
guthriet@wustl.edu
Washington University School of Medicine
Interventions
  • Procedure: Peripheral blood draw
  • Procedure: Breast tissue collection
  • Procedure: Bone marrow biopsy
Study Locations (1 sites)
Washington University School of Medicine, St Louis, Missouri 63119 United States
Eligibility Criteria
Inclusion Criteria: * Recently diagnosed with clinical stage II, III, or IV breast cancer * Planning to undergo neoadjuvant or adjuvant systemic therapy; patients who have already completed neoadjuvant systemic therapy are also eligible * Must be \>= 18 years of age * If female, must not be pregnant * Must not have Hepatitis B, C, or HIV * Must be willing and able to sign informed consent document
Conditions Breast Cancer (Early Breast Cancer)
Phase PHASE2
Enrollment 700
Locations 41 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to determine whether a selected population of women with early-stage, low-risk breast cancer can avoid hormone therapy without increasing their risk of relapse. It will also evaluate the prognosis of these participants compared to participants who received standard treatment with hormone therapy in another study, estimate the risk of specific recurrence, cardiovascular and bone health, and participants' quality of life. All participants will have undergone surgery and possibly radiation therapy, but unlike standard care, they will not receive hormone therapy afterward. Participants will be enrolled for two years and followed for up to five years after the last participant is enrolled in the trial to monitor for long-term cancer recurrence.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Removing Endocrine Therapy — The standard of care endocrine therapy (Tamoxifene, Letrozole, Anastrozole or Exemestane) will not be received by the participant during the study.

Primary Outcomes

  • Relapse-free interval (At 5 years after the last treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-07-06
Completion: 2033-07-06
Eligibility
Age: 60 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 700 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: UNICANCER
Collaborators: Swiss Cancer Institute
Principal Investigators:
  • Jean-Yves PIERGA, MD (PRINCIPAL_INVESTIGATOR) - Institut Curie
  • José Luis SANDOVAL, MD (PRINCIPAL_INVESTIGATOR) - University Hospital, Geneva
Contact Information
Study Contact:
Unicancer Project Leader
0033 6 58 43 58 94
a-poitou@unicancer.fr
Dr PATSOURIS
Ico Angers
Dr BRACHET
CH Aunay-Bayeux
Interventions
  • Drug: Removing Endocrine Therapy — The standard of care endocrine therapy (Tamoxifene, Letrozole, Anastrozole or Exemestane) will not be received by the participant during the study.
Study Locations (41 sites)
Ico Angers, Angers, France
Sainte Catherine, Institut du Cancer Avignon-Provence, Avignon, France
CH Aunay-Bayeux, Bayeux, France
CHCB, Bayonne, France
Clinique Tivoli, Bordeaux, France
Institut Bergonié, Bordeaux, France
CH Boulogne sur mer, Boulogne-sur-Mer, France
Clinique Pasteur Lanroze, Brest, France
CH de Bligny, Briis-sous-Forges, France
Centre Francois Baclesse, Caen, France
Eligibility Criteria
Inclusion Criteria: * Postmenopausal (underwent bilateral oophorectomy or non-chemo induced amenorrhea for 12 or more months) female participant ≥60 years of age. * New diagnosis of invasive carcinoma of the breast (ductal, tubular or mucinous) with primary tumor ≤1 cm on microscopic exam with no evidence of nodal or distant metastatic disease. * Contralateral breast described as BI-RADS (Breast Imaging-Reporting And Data System) 1 or 2 in diagnostic imaging. * Negative axillary node involvement by sentinel node biopsy or axillary node dissection (pN0) or Clinically negative axillary node involvement (cN0) after mandatory ultrasound exploration without surgical exploration of the axilla if Breast Conservative Surgery (BCS) was performed. * Estrogen Receptor (ER) positive (≥ 50%) and Progesterone Receptor(PR) positive (\> 20%), Ki67 low (≤15%) and HER2 negative (IHC or In Situ Hybridization approach) according to ASCO (American Society of Clinical Oncology) criteria. * Histological grade scored on the invasive component, 1 or 2 if pT1a or grade 1 if pT1b. * Treated by mastectomy or BCS with microscopically clear resection margins defined as "no-ink on tumor" or ≥1 mm for invasive and non-invasive disease or no residual disease on re-excision. * If BCS was performed, participants must have received or have scheduled adjuvant local radiotherapy (RT) within 3 months after surgery * No indication of adjuvant chemotherapy. * The participant is willing and able to comply with the protocol for the duration of the study, including scheduled visits, treatment strategy, laboratory tests and other study procedures. * Participants must be affiliated with a Social Security System (or equivalent). * The participant must have signed a written informed consent form before any trial-specific procedures. When the participant is physically unable to give written consent, an impartial witness of her choice, independent from the investigator or the sponsor, can confirm the participant's consent in writing. Exclusion Criteria: * Have received any neo-adjuvant treatment, including hormone therapy and chemotherapy. * Have received or are eligible for adjuvant chemotherapy. * Absolute contraindication for RT in case of BCS or patients who were treated with partial breast irradiation. * Have been treated with mastectomy and with adjuvant radiotherapy received or scheduled. * Invasive lobular breast cancer. * Bilateral breast cancer or history of other invasive ipsi- or contralateral breast cancer. * Multifocal or multicentric disease. * Disease limited to microinvasion only (\< 1 mm). * Evidence of lymphovascular invasion. * History of non-breast cancer malignancies if not disease-free for \> 5 years and considered low risk of recurrence except for treated carcinoma in situ of the cervix, endometrium or colon, melanoma in situ and basal or squamous cell carcinoma of the skin. * Non-malignant severe disease associated with a life expectancy \< 10 years. * Women with BRCA1, BRCA2 or other high-risk breast cancer predisposing deleterious germline mutations. * Enrolled in another therapeutic study within 30 days prior to inclusion. * Unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons. * Persons deprived of their liberty or under protective custody or guardianship.